YOLFTbeta
INVEX Therapeutics Ltd

INVEX Therapeutics Ltd

IXC · AU · Healthcare / Biotechnology

0.085AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.085
Open0.088
Day Range0.085 – 0.088
52-Week Range0.09 – 0.15
Volume3.04K
Market Cap8.27M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta0.54
50-Day Avg0.1139
200-Day Avg0.1135

About

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Timothy Ryan Slate
  • Employees0
  • Headquarters101 St Georges Terrace, Perth, WA, Australia, 6000, Australia
  • Websitehttps://www.invextherapeutics.com

Leadership

  • Mr. Timothy Ryan SlateCompany Secretary

Financials

Income Statement

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue130165.70K158.79K182.25K459.08K1.21M229.08K-
Growth (%)-+127361.54%-4.17%+14.77%+151.90%+164.00%-81.10%-
Gross Profit396--182.25K459.08K1.21M229.08K-
Gross Margin304.62%--100.00%100.00%100.00%100.00%-
Operating Expense232.40K--4.22M9.01M3.35M938.39K-
Operating Income-232.00K-3.29M-2.44M-4.03M-8.55M-2.13M-709.30K-1.54M
Operating Margin-178461.54%-1985.57%-1538.51%-2212.88%-1861.75%-176.07%-309.63%-
EBITDA-314.91K-3.29M-2.28M-4.14M-8.21M-720.00K-951.22K-1.54M
EBITDA Margin-242238.46%-1985.57%-1438.32%-2269.06%-1788.11%-59.41%-415.23%-
Net Income-232.00K-3.36M-2.28M-3.95M-7.75M-1.64M-476.87K-1.35M
Net Income Margin-178461.54%-2027.93%-1438.38%-2168.99%-1688.14%-135.48%-208.16%-
R&D59.88K1.59M1.14M2.96M7.40M2.04M204.50K520.39K
R&D as % of Total Revenue46058.46%960.50%717.30%1625.78%1611.90%168.23%89.27%-
Interest Expense00079.88K----
Interest Expense % of Total Revenue0.00%0.00%0.00%43.83%----

Balance Sheet

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets12.37M26.42M32.74M29.49M22.80M6.12M5.47M4.06M
Total Liabilities935.49K2.02M658.61K1.00M1.57M431.63K220.59K153.47K
Total Equity11.44M24.40M32.08M28.48M21.23M5.69M5.25M3.91M
Cash12.17M26.30M32.72M29.34M22.47M6.03M5.38M1.52M
Net Debt-12.17M-26.30M-32.72M-29.34M-22.47M-6.03M-5.38M-1.52M

Cash Flow

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-230.13K-1.60M-1.68M-3.38M-6.87M-2.44M-652.57K-1.36M
Investing Cash Flow-8.19K0------2.50M
Financing Cash Flow12.41M15.73M8.09M00-14.00M0-
Capital Expenditure8.19K0500000
Free Cash Flow-238.32K-1.60M-1.68M-3.38M-6.87M-2.44M-652.57K-1.36M
FCF to OCF103.56%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateFeb 27, 2020Aug 27, 2020Feb 15, 2021Aug 26, 2021Feb 22, 2022Aug 18, 2022Feb 17, 2023Feb 6, 2025Aug 10, 2025
EPS Estimate0.000.000.00----0.000.00
EPS Actual-0.02-0.04-0.01-0.02-0.02-0.03-0.050.000.00
Surprise---------
Timing-----After-hoursPre-market--

Key Statistics & Ratios

Market Cap8.27M
Enterprise Value3.87M
Trailing P/E0.00
Forward P/E0.00
Price / Sales176.55
Price / Book2.02
EPS-0.02
Book Value0.052
Revenue (TTM)46.83K
Gross Profit (TTM)46.83K
Profit Margin0.00%
Operating Margin-1397.89%
Return on Equity-29.54%
Return on Assets-19.64%
Shares Outstanding75.15M
Shares Float48.97M
Beta0.54
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.19Dec 8, 2023